Companies /Healthcare

BridgeBio Pharma Inc

NASDAQ: BBIO Biotechnology
$78.68
▼ $0.69 (−0.87%) today
Markets closed · 10:15pm ET

Q1 2025 Earnings

Reported Apr 29, 2025, 4:04pm ET · SEC source
$-0.88
Beat +11.78%
EPS · est. $-1.00
$116.6M
Beat +102.06%
Revenue · est. $57.7M
−14.4%
Trailing market
BBIO vs S&P since report
5 quarters
Consecutive EPS misses

Market Reaction

% change · around the report
−8%−4%0Apr 29Apr 30report 4:04pm ETearnings+0.8%−3.6%
−8%−4%0Apr 29Apr 30earnings+0.8%−3.6%
BBIO −3.6%S&P 500 +0.8%
−8%−4%0Apr 29Apr 30report 4:04pm ETearnings+1.4%−3.6%
−8%−4%0Apr 29Apr 30earnings+1.4%−3.6%
BBIO −3.6%NASDAQ +1.4%
−8%−4%0+4%Apr 28May 7report 4:04pm ETearnings+1.2%−8.5%
−8%−4%0+4%Apr 28May 7earnings+1.2%−8.5%
BBIO −8.5%S&P 500 +1.2%
−8%−4%0+4%Apr 28May 7report 4:04pm ETearnings+1.8%−8.5%
−8%−4%0+4%Apr 28May 7earnings+1.8%−8.5%
BBIO −8.5%NASDAQ +1.8%
+5.33%
Day of report
+0.10%
Next session
−6.62%
One week
−7.56%
30 days

S&P 500 over the same 30 days: +6.88%.

Did BBIO Beat Earnings? Q1 2025 Results

BridgeBio Pharma delivered a clear beat across both top and bottom lines in Q1 2025, posting a loss of $0.88 per share against a consensus estimate of $1.00, an 11.78% positive surprise, while revenue of $116.63 million more than doubled analyst expectations of $57.72 million by 102.06%. The headline revenue figure came in 44.8% below the prior-year period, but that decline was largely mechanical, reflecting the absence of the large upfront license payments from the Bayer and Kyowa Kirin agreements that inflated Q1 2024 results. The more telling signal was the $75 million regulatory milestone tied to the European Commission's approval of BEYONTTRA, combined with $36.74 million in Attruby net product revenue, its first full commercial quarter in the U.S. Looking ahead, BridgeBio expects an additional $105 million in milestone payments in Q2 for further ex-U.S. BEYONTTRA approvals, while key pipeline readouts for encaleret, BBP-418, and infigratinib are scheduled across the second half of 2025.

Key Takeaways
  • First full quarter of Attruby U.S. commercial sales generating $36.7 million in net product revenue
  • $75 million regulatory milestone from European Commission approval of BEYONTTRA under Bayer collaboration
  • 2,072 unique patient prescriptions written by 756 unique healthcare providers since FDA approval
  • SG&A expense increase to support Attruby commercial launch, partially offset by R&D cost reductions from affiliate divestitures

“I'm grateful that Attruby has found a place and is continuing to grow in the front line of the ATTR-CM paradigm. This success is due to its stellar clinical efficacy, safety profile, and the access work we have done to ensure patients in need can get our drug. As we continue to demonstrate our commercial capabilities, I'm also pleased to observe our continued distinctive performance in clinical development – this quarter's announcements regarding our hypochondroplasia and hypoparathyroidism programs are good examples of our speed and breadth of capabilities.”

BridgeBio Pharma CEO, on the earnings call

Forward Guidance & Outlook

BridgeBio anticipates receiving $105 million in regulatory milestone payments in Q2 2025 for ex-U.S. approvals of BEYONTTRA. Multiple pipeline readouts are expected in H2 2025: FORTIFY interim analysis (BBP-418 for LGMD2I/R9), CALIBRATE topline results (encaleret for ADH1), and last-participant-last-visit for PROPEL 3 (infigratinib for achondroplasia), with PROPEL 3 topline results expected in early 2026. The company plans to initiate clinical development of infigratinib in children with achondroplasia from birth to less than 3 years old by year-end 2025, and intends to advance encaleret to a registrational study in chronic hypoparathyroidism. The first participant in the ACT-EARLY Phase 3 study for acoramidis is expected to be dosed in 2025.

BBIO YoY Financials

Q1 2025 vs Q1 2024 · SEC filings Q1 2024 Q1 2025
$0$60.0M$120.0M$180.0M$211.1M$116.6MRevenue$210.5M$114.0MGross Profit
$0$60.0M$120.0M$180.0MRevenueGross Profit

BBIO Revenue by Segment

Attruby
License and Services Revenue$79.9M
Attruby (acoramidis) - U.S. Net Product Revenue
Attruby (acoramidis) - Net Product Revenue$36.7M
Royalty Revenue (BEYONTTRA)
BEYONTTRA Royalty Revenue

Figures from SEC filings and company reports. Not investment advice.